glioblastoma
Conditions
Interventions
blood collection for cell culture and tests.
Administration of therapeutic cells(neoantigen DC) 6 times and cells(2DG-CTL ) 6 times
Sponsors
Kondo Akihide
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1)Diagnosed with IDH-unmutated glioblastoma. (2) Have a successful genetic analysis of tumor sample. (3)Be at score 70 or over of Karnofsky Performance Status (KPS). (4)Be expected to survive for 3months or longer after initiation of the study therapy. (5)Be at age 20 or older. (6)Visit outpatient department. (7)Have an adequate function of liver, kidney, and bone marrow when eligibility is confirmed. (8)Provide written consent to participate this study.
Exclusion criteria
Exclusion criteria: (1)Be apparent from the clinical manifestation of pulmonary fibrosis or interstitial pneumonia. (2)Have a history of a serious drug allergy. (3)Have a positive result of HIV or HTLV-1 antibody test. (4)Have a serious cardiac disorder. (5)Have an active autoimmune disorder. (6)Have a cancer other than glioma. (7)Have an infectious disorder that is difficult to control. (8) Patients with postoperative recurrence after standard treatment (surgery, chemoradiation). (9)Be a female who is pregnant. (10)A patient who is judged as inadequate for enrolment by doctors is excluded
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety | — |
Secondary
| Measure | Time frame |
|---|---|
| Efficacy, Immunological response, Quality of therapeutic cells, Quality of life | — |
Countries
Japan
Contacts
Public ContactTakashi Kamigaki
Juntendo University
Outcome results
None listed